Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | huntingtin | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Homo sapiens | hydroxyprostaglandin dehydrogenase 15-(NAD) | Starlite/ChEMBL | No references |
Homo sapiens | K(lysine) acetyltransferase 2A | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | steroid dehydrogenase, putative | hydroxyprostaglandin dehydrogenase 15-(NAD) | 266 aa | 216 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | dihydropyridine-sensitive l-type calcium channel | 0.0081 | 0.1057 | 0.0484 |
Schistosoma mansoni | dihydropyridine-sensitive l-type calcium channel | 0.0161 | 0.3537 | 0.8598 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.0909 | 0.0208 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.0909 | 0.0208 |
Giardia lamblia | Histone acetyltransferase GCN5 | 0.0047 | 0 | 0.5 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-B | 0.0051 | 0.0133 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0087 | 0.1229 | 0.1046 |
Brugia malayi | RNA binding protein | 0.0076 | 0.0909 | 0.0208 |
Plasmodium falciparum | histone acetyltransferase GCN5 | 0.0047 | 0 | 0.5 |
Onchocerca volvulus | Huntingtin homolog | 0.0148 | 0.3126 | 0.5 |
Echinococcus multilocularis | voltage dependent calcium channel subunit | 0.0168 | 0.375 | 0.3125 |
Trichomonas vaginalis | bromodomain-containing protein, putative | 0.0051 | 0.0133 | 0.5 |
Trichomonas vaginalis | cat eye syndrome critical region protein 2, cscr2, putative | 0.0051 | 0.0133 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.0909 | 0.0208 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 0.3126 | 0.7308 |
Onchocerca volvulus | Huntingtin homolog | 0.0148 | 0.3126 | 0.5 |
Entamoeba histolytica | acetyltransferase, GNAT family | 0.0047 | 0 | 0.5 |
Echinococcus multilocularis | voltage dependent calcium channel subunit | 0.037 | 1 | 1 |
Echinococcus multilocularis | gcn5proteinral control of amino acid synthesis | 0.0175 | 0.3966 | 0.3362 |
Schistosoma mansoni | serine-rich repeat protein | 0.0087 | 0.1229 | 0.1046 |
Loa Loa (eye worm) | acetyltransferase | 0.0175 | 0.3966 | 1 |
Echinococcus granulosus | histone acetyltransferase KAT2B | 0.017 | 0.3814 | 0.373 |
Schistosoma mansoni | gcn5proteinral control of amino-acid synthesis 5-like 2 gcnl2 | 0.0175 | 0.3966 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.0909 | 0.0787 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.0909 | 0.0208 |
Echinococcus granulosus | voltage dependent calcium channel subunit | 0.0168 | 0.375 | 0.3666 |
Toxoplasma gondii | histone lysine acetyltransferase GCN5-A | 0.0051 | 0.0133 | 0.5 |
Plasmodium vivax | histone acetyltransferase GCN5, putative | 0.0051 | 0.0133 | 0.5 |
Brugia malayi | acetyltransferase, GNAT family protein | 0.0175 | 0.3966 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.0909 | 0.0208 |
Brugia malayi | hypothetical protein | 0.0148 | 0.3126 | 0.7308 |
Loa Loa (eye worm) | hypothetical protein | 0.0148 | 0.3126 | 0.7308 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.5012 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.8913 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Potency (functional) | = 1.2589 um | PUBCHEM_BIOASSAY: qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP). (Class of assay: confirmatory) [Related pubchem assays: 1482, 1471 ] | ChEMBL. | No reference |
Potency (functional) | = 14.1254 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. This assay monitors tau fibrillation by fluorescence polarization (FP) of Alexa 594-labeled K18 P301L, which does not fibrillize readily but incorporates into growing filaments of unlabeled tau. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.